Abstract: A dual color electronically addressable ink includes a positively charged ink and a negatively charged ink. The positively charged ink includes a non-polar carrier fluid, pigment-loaded basic resin particles having a first color, and an acceptor charge adjuvant. The negatively charged ink includes the non-polar carrier fluid, pigment-loaded acidic resin particles having a second color that is different than the first color, and a donor charge adjuvant. The dual color electronically addressable ink also includes at least one charge director.

Abstract: A dual color electronically addressable ink includes a non-polar carrier fluid; a first colorant of a first color; and a second colorant of a second color that is different than the first color. The first colorant includes a first particle core, and a first functional group attached to a surface of the particle core. The first functional group is capable of carrying a positive charge and is chosen from a base or a salt of the base. The second colorant includes a particle core, and a second functional group attached to a surface of the particle core. The second functional group is capable of carrying a negative charge and is chosen from an acid or a salt of the acid. The ink further includes an additive chosen from polyhydroxystearic amide salt, polyhydroxystearic acid, aromatic butyric acid, and combinations thereof.

Abstract: A dual color electronically addressable ink includes a positively charged ink and a negatively charged ink. The positively charged ink includes a non-polar carrier fluid, pigment-loaded basic resin particles having a first color, and an acceptor charge adjuvant. The negatively charged ink includes the non-polar carrier fluid, pigment-loaded acidic resin particles having a second color that is different than the first color, and a donor charge adjuvant. The dual color electronically addressable ink also includes at least one charge director.

Abstract: A current limiting device (30, 40, 50, 60) comprising for each phase of an AC supply a closed magnetic core (31) of reduced volume and mass having first and second pairs of opposing limbs (32a, 32b; 33a, 33b), and at least one AC coil (35a, 35b) enclosing opposing limbs (33a, 33b) of the magnetic core (31) and adapted for series connection with a load. A superconducting DC bias coil (34) encloses a limb) (32a, 32b) of the magnetic core (31) for saturating each of the opposing limbs (33a, 33b) in opposite directions by the bias coil (34). Under fault conditions, the AC flux in at least one limb counteracts the DC bias flux, bringing the limb out of saturation. Preferably, current is reduced in the DC bias coils thus bringing both opposing limbs of the core out of saturation.

Abstract: Positively charged ink compositions, its use and method of making the same are disclosed. A disclosed example of the positively charged ink compositions includes a combination of a carrier liquid, basic pigment-loaded resin particles, a charge director and an acidic charge adjuvant.

Abstract: A system and method for identifying potential customers is provided. Information in a proprietary data repository of a company may be analyzed to thereby determine a first set of textual terms. Publicly available information related to the existing customer set may be analyzed to thereby determine a second set of textual terms. Terms in the first and second sets may be associated with scores. A customer profile may be generated based on the textual terms and associated scores. Potential customers may be identified based on the buyer profile. Other embodiments are described and claimed.

Abstract: A three-phase current limiter (30) for an alternating current system includes an AC magnetic circuit having at least one AC coil (35R1, 35S1, 35T1) for each phase of a 3-phase AC supply wound on a saturable ferromagnetic core and configured to subject respective AC coils for each phase to a common magnetic flux, and a DC magnetic circuit (34a, 34b) for biasing the AC magnetic circuit into saturation at normal conditions. In use the AC coils are connected in series with a load and during alternate half cycles of the AC supply at least one of the AC coils produces a magnetic field that opposes a magnetic field of the DC magnetic circuit. The AC coils (35R, 35S, 35T) for each phase are configured so that at least one of the AC coils exhibits unbalanced magnetic impedance relative to remaining ones of the AC coils for each phase.

Abstract: A current limiting device (30, 40, 50, 60) comprising for each phase of an AC supply a closed magnetic core (31) of reduced volume and mass having first and second pairs of opposing limbs (32a, 32b; 33a, 33b), and at least one AC coil (35a, 35b) enclosing opposing limbs (33a, 33b) of the magnetic core (31) and adapted for series connection with a load. A non-superconducting DC bias coil (34) typically formed of copper encloses a limb (32a, 32b) of the magnetic core (31) for saturating each of the opposing limbs (33a, 33b) in opposite directions by the bias coil (34). Under fault conditions, the AC flux in at least one limb counteracts the DC bias flux, bringing the limb out of saturation. Preferably, current is reduced in the DC bias coils thus bringing both opposing limbs of the core out of saturation.

Abstract: A system including a platform having a receptacle adapted to a bottom of a shoe or foot; securing mechanism, associated therewith; a sole for contacting a ground surface; a mechanism associated with the sole and a platform bottom, including: motor and a thrusting element, activated by the motor, the thrusting element adapted to move between the sole and the platform to apply an upward force against the platform bottom, thereby changing a platform height with respect to the sole; a sensor device adapted to associate with a lower limb, and to produce a locomotion data signal, and a microprocessor, operatively connected to the sensor device and motor, adapted to: receive locomotion information based on the signal; process the locomotion information to determine a locomotion phase, and control a timing of the mechanism, based on the determination, to change the height during a locomotion swing phase.

Abstract: The invention generally relates to thienopyridinone 5-HT4 receptor modulators, and in particular the use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with serotonin action, such as in treating Alzheimer's disease, cognition disorders, depression, and anxiety.

Abstract: Toner compositions, treated fluoropolymer particles, methods of making treated fluoropolymer particles, and the like, are disclosed.

Abstract: The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.

Abstract: Ink toners, methods of making ink, and methods of changing viscosity are disclosed.

Abstract: The invention relates to 5-HT receptor antagonists. Novel piperidinylamino-thieno [2,3-d] pyrimidine compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as pulmonary arterial hypertension, migraine, hypertension, disorders of the gastrointestinal tract, restenosis, asthma, obstructive airway disease, prostatic hyperplasia and priapism, anxiety, depression, schizophrenia, neural injury and stroke. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also provided.

Abstract: The invention is a dosing pump that can be worn on the body of a patient for subcutaneously delivering liquid with centi-micro liter accuracy to his/her body. The dosing pump comprises a pump unit, an internal control unit; and a reservoir containing the liquid. The pump unit comprises a pump block (12) comprising a pump chamber (118) with a pump diaphragm (107) stretched across its entrance and a pump pin cylinder (110) extending from the exterior of the pump block to the entrance to the pump chamber; a pump pin (20) that is located in the pump pin cylinder and a motor unit comprising a motor and gear system. When the motor is activated, the rotational motion of the motor and the gears in the gear system is transformed into cyclic back and forth linear motion of the pump pin in the pin cylinder pumping the liquid from the reservoir into the patient.

Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.

Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.

Abstract: The invention relates to 5-HT receptor modulators, particularly 5-HT2B antagonists. Novel piperidinylamino-thieno[2,3-d]pyrimidine compounds represented by Formula I, II and III, and uses thereof for treating conditions including pulmonary arterial hypertension, congestive heart failure, and hypertension.

Abstract: The invention relates to 5-HT receptor modulators, particularly 5-HT2B antagonists. Novel piperidinylamino-thieno[2,3-d]pyrimidine compounds represented by Formula I, II and III, and uses thereof for treating conditions including pulmonary arterial hypertension, congestive heart failure, and hypertension.